Tenax Therapeutics (TENX) Price & Analysis

Compare

586 Followers

TENX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.30 - $8.00

Previous CloseN/A

Volume25.45K

Average Volume (3M)95.50K

Market Cap

$34.17M

Enterprise Value$122.47M

Total Cash (Recent Filing)$105.46M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.06

Next Earnings

Nov 12, 2025

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding4,562,500

10 Day Avg. Volume156,976

30 Day Avg. Volume95,504

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap3.58

Enterprise Value/Revenue61.24K

Enterprise Value/Gross Profit122.47K

Enterprise Value/Ebitda-3.89

Forecast

1Y Price Target

$17.00

Price Target Upside117.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial StabilityTENX has reported $105.5 million in cash and cash equivalents, providing a cash runway through 2027.

Market PotentialTENX is a small market cap company with the potential to become specifically approved in the high unmet need PH-HFpEF indication.

Patent ProtectionThe European Patent Office plans to grant patent protection in Europe for the use of levosimendan in pulmonary hypertension resulting from heart failure with preserved ejection fraction, enhancing Tenax's market position.

Bears Say

Increased ExpensesR&D and SG&A expenses for the quarter were higher than expected, totaling $6 million each.

Regulatory And Commercial RisksClinical, regulatory, commercial and financing risks exist for TNX-103 in Group 2 PH-HFpEF.

Trial DelaysThe timeline for the Ph3 LEVEL Study in PH-HFpEF has been delayed, with topline data now expected in the second half of 2026.

Tenax Therapeutics News

Tenax Therapeutics management to meet with Piper Sandler

Meeting to be held in New York on October 8-9 hosted by Piper Sandler. Published first on TheFly...

9d ago

TENX

Tenax announces EPO intention to grant patent for levosimendan in PH-HFpEF

Tenax Therapeutics (TENX) announced that the European Patent Office, EPO, has notified Tenax of its Intention to Grant...

24d ago

TENX

Optimistic Buy Rating for Tenax Therapeutics Driven by Strong Patent Portfolio and Market Potential of Levosimendan

William Blair analyst Matt Phipps has reiterated their bullish stance on TENX stock, giving a Buy rating on...

24d ago

TENX

Tenax Therapeutics Expands Licensing Agreement with Orion

Tenax Therapeutics ( ($TENX) ) just unveiled an update. On September 3, 2025, Tenax Therapeutics expanded its licensing...

1M ago

TENX

Promising Potential of Tenax Therapeutics’ TNX-103 Drives Buy Rating Amid Positive Phase 2 Results and Anticipated Phase 3 Trial

Yasmeen Rahimi, an analyst from Piper Sandler, has initiated a new Buy rating on Tenax Therapeutics (TENX). Yasmeen...

1M ago

TENX

Tenax Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tenax Therapeutics (TENX) with an Overweight rating and $20 price...

1M ago

TENX

Tenax Therapeutics Reports Q2 2025 Financial Results

Tenax Therapeutics ( ($TENX) ) has released its Q2 earnings. Here is a breakdown of the information Tenax...

2M ago

TENX

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

“We are pleased with the progress achieved in the second quarter, and remain in a strong position to...

2M ago

TENX

Tenax Therapeutics trading resumes

13:44 EDT Tenax Therapeutics (TENX) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

4M ago

TENX

Tenax Therapeutics trading halted, volatility trading pause

13:39 EDT Tenax Therapeutics (TENX) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

4M ago

TENX

Tenax Therapeutics Approves Officer Exculpation Amendment

Tenax Therapeutics ( ($TENX) ) has shared an announcement. On June 11, 2025, Tenax Therapeutics held its annual...

4M ago

TENX

Tenax Therapeutics Reports Increased Losses Amid Strategic Investments

Tenax Therapeutics ( ($TENX) ) has released its Q1 earnings. Here is a breakdown of the information Tenax...

5M ago

TENX

Positive Buy Rating for Tenax Therapeutics Driven by Promising Clinical Trials and Strong Financial Position

Leerink Partners analyst David Risinger reiterated a Buy rating on Tenax Therapeutics (TENX – Research Report) on May...

5M ago

TENX

Tenax Therapeutics price target lowered to $15 from $16 at Guggenheim

Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Tenax Therapeutics (TENX) to $15 from $16 and...

5M ago

TENX

TENX FAQ

What was Tenax Therapeutics’s price range in the past 12 months?

Tenax Therapeutics lowest stock price was $3.30 and its highest was $8.00 in the past 12 months.

What is Tenax Therapeutics’s market cap?

Tenax Therapeutics’s market cap is $34.17M.

When is Tenax Therapeutics’s upcoming earnings report date?

Tenax Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 33 days.

How were Tenax Therapeutics’s earnings last quarter?

Tenax Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.266 by -$0.004.

Is Tenax Therapeutics overvalued?

According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tenax Therapeutics pay dividends?

Tenax Therapeutics does not currently pay dividends.

What is Tenax Therapeutics’s EPS estimate?

Tenax Therapeutics’s EPS estimate is -0.31.

How many shares outstanding does Tenax Therapeutics have?

Tenax Therapeutics has 4,562,500 shares outstanding.

What happened to Tenax Therapeutics’s price movement after its last earnings report?

Tenax Therapeutics reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.266. Following the earnings report the stock price went up 0.677%.

Which hedge fund is a major shareholder of Tenax Therapeutics?

Currently, no hedge funds are holding shares in TENX

Tenax Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-56.12%

Trailing 12-Months

Asset Growth

897.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tenax Therapeutics

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing pharmaceutical products for the critical care market. The company primarily operates in the biotechnology and pharmaceutical sectors, with its core product offerings centered around novel therapeutic solutions for pulmonary hypertension and other cardiovascular diseases. Tenax Therapeutics is committed to advancing clinical programs and leveraging its expertise to bring innovative treatments to market that address unmet medical needs.

Tenax Therapeutics (TENX) Earnings & Revenues

Historic Earnings Reports

TENX Stock 12 Month Forecast

Average Price Target

$17.00

▲(117.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.98,7.058461538461539,8.136923076923077,9.215384615384615,10.293846153846154,11.372307692307693,12.45076923076923,13.529230769230768,14.607692307692307,15.686153846153847,16.764615384615382,17.84307692307692,18.92153846153846,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.98,6.827692307692308,7.6753846153846155,8.523076923076923,9.37076923076923,10.21846153846154,11.066153846153846,11.913846153846155,12.76153846153846,13.60923076923077,14.456923076923077,15.304615384615385,16.152307692307694,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.98,6.596923076923077,7.213846153846154,7.830769230769231,8.447692307692307,9.064615384615385,9.681538461538462,10.298461538461538,10.915384615384616,11.532307692307693,12.149230769230769,12.766153846153847,13.383076923076924,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >